BioSense Technologies, a pioneer in the development of diagnostic
systems for rapid drug susceptibility testing, announced today that it
presented key scientific findings at the National Foundation for
Infection Disease 2010 Annual Conference on Antimicrobial Resistance,
held in Bethesda, MD in early February. The Company presented compelling
scientific data in a poster presentation (www.biosensetech.com/publications.htm)
demonstrating that its Z-Sense™ Differential Impedance Sensing
diagnostic system rapidly and accurately identified the drug
susceptibility of bacteria, yeast, and cancer cells exposed to
therapeutic agents in near real-time. The growing resistance of bacteria
to antibiotics combined with the shortage of available new drugs
threatens the ability to cure infections that were previously treatable.
“Our technology has the potential to dramatically improve the treatment
of life threatening diseases such as cancer and antibiotic resistant
bacterial infections”
The Company’s findings were also accepted and published in the November
2009 issue of Antimicrobial Agents and Chemotherapy. This journal
article reported that the Z-Sense™ system distinguished susceptible from
resistant strains of slow-growing tuberculosis bacteria exposed to
anti-tuberculosis drugs in less than one hour.